NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Inclusion Criteria: * Histologically confirmed GBM * Progressive disease after temozolomide and radiation therapy (in "first relapse") * At least 28 days since chemotherapy or radiation * Karnofsky performance score at least 70% * Platelet count \>= 130/mm\^3 * Absolute neutrophil count \>= 1500/mm\^3 * Calculated creatinine clearance greater than 45 mg/dl using the Cockcroft-Gault formula * Aspartate aminotransferase (AST) \< 2 times the upper limit of normal * Bilirubin \< 1.5 times the upper limit of normal * Subjects with child-bearing potential agree to use effective means of contraception Exclusion Criteria: * Prior systemically administered nitrosoureas or vascular endothelial growth factor (VEGF) targeted therapy * Chemotherapy for glioma other than temozolomide or Gliadel wafers (steroids are allowed) * Pregnant or breast feeding * Active inflammatory bowel disease * Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months * Hypertension: systolic blood pressure (SBP) \> 150 or diastolic blood pressure (DBP) \> 100 mm mercury (Hg) despite antihypertensive medications * New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF); myocardial infarction or unstable angina within 6 months * History of thrombosis * Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6 months * Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within 28 days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days * Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds (normal range 21.8-31.5 seconds); international normalized ratio (INR) must not exceed 1.30 (normal range 0.87-1.18) * Serious, non-healing wound, ulcer, or bone fracture * Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts), a skull defect (such as missing bone with no replacement), a shunt, or bullet fragments * Known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes * Human immunodeficiency virus (HIV) positive * Proteinuria at screening as demonstrated by urine dipstick \>= 2+ * Prior organ transplantation * Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel or any other drug whose goal is to inhibit platelet function * Unable to give signed informed consent